NYSE:RMD - ResMed Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $112.90 +2.91 (+2.65 %) (As of 12/10/2018 04:00 PM ET)Previous Close$109.99Today's Range$110.11 - $113.1652-Week Range$83.88 - $116.64Volume1.05 million shsAverage Volume717,027 shsMarket Capitalization$15.67 billionP/E Ratio31.98Dividend Yield1.32%Beta1.01 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; data communications and control products, such as AirView Diagnostics, EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules; U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night's data, as well as offers business management software and services to medical equipment and home health providers. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. Receive RMD News and Ratings via Email Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:RMD Previous Symbol CUSIP76115210 Webwww.resmed.com Phone858-836-5000 Debt Debt-to-Equity Ratio0.27 Current Ratio2.58 Quick Ratio1.91 Price-To-Earnings Trailing P/E Ratio31.98 Forward P/E Ratio30.60 P/E Growth2.81 Sales & Book Value Annual Sales$2.34 billion Price / Sales6.87 Cash Flow$4.5142 per share Price / Cash Flow25.01 Book Value$14.43 per share Price / Book7.82 Profitability EPS (Most Recent Fiscal Year)$3.53 Net Income$315.58 million Net Margins13.94% Return on Equity26.29% Return on Assets15.99% Miscellaneous Employees5,940 Outstanding Shares142,500,000Market Cap$15.67 billion OptionableOptionable ResMed (NYSE:RMD) Frequently Asked Questions What is ResMed's stock symbol? ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD." How often does ResMed pay dividends? What is the dividend yield for ResMed? ResMed announced a quarterly dividend on Friday, October 26th. Shareholders of record on Thursday, November 8th will be given a dividend of $0.37 per share on Thursday, December 13th. This represents a $1.48 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date is Wednesday, November 7th. View ResMed's Dividend History. How were ResMed's earnings last quarter? ResMed Inc. (NYSE:RMD) posted its quarterly earnings data on Thursday, October, 25th. The medical equipment provider reported $0.81 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.80 by $0.01. The medical equipment provider had revenue of $588.28 million for the quarter, compared to analyst estimates of $576.66 million. ResMed had a return on equity of 26.29% and a net margin of 13.94%. View ResMed's Earnings History. When is ResMed's next earnings date? ResMed is scheduled to release their next quarterly earnings announcement on Monday, January 28th 2019. View Earnings Estimates for ResMed. What price target have analysts set for RMD? 9 brokerages have issued 1 year price targets for ResMed's shares. Their predictions range from $127.00 to $127.00. On average, they expect ResMed's stock price to reach $127.00 in the next year. This suggests a possible upside of 12.5% from the stock's current price. View Analyst Price Targets for ResMed. What is the consensus analysts' recommendation for ResMed? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ResMed. Has ResMed been receiving favorable news coverage? Media coverage about RMD stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ResMed earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the company's share price in the immediate future. Who are some of ResMed's key competitors? Some companies that are related to ResMed include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Haemonetics (HAE), Insulet (PODD), ICU Medical (ICUI), Penumbra (PEN), Globus Medical (GMED), Integra Lifesciences (IART), Cantel Medical (CMD) and Merit Medical Systems (MMSI). Who are ResMed's key executives? ResMed's management team includes the folowing people: Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 46)Mr. Robert A. Douglas, Pres & COO (Age 58)Mr. Brett A. Sandercock, Chief Financial Officer (Age 51)Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 59)Mr. James Hollingshead, Pres of Sleep Bus. (Age 55) Who are ResMed's major shareholders? ResMed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.22%), BlackRock Inc. (7.85%), FMR LLC (5.52%), Capital World Investors (4.93%), Baillie Gifford & Co. (3.40%) and Bank of New York Mellon Corp (1.15%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed. Which institutional investors are selling ResMed stock? RMD stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Mitsubishi UFJ Trust & Banking Corp, Great Lakes Advisors LLC, First Trust Advisors LP, Korea Investment CORP, Allianz Asset Management GmbH and West Coast Financial LLC. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed. Which institutional investors are buying ResMed stock? RMD stock was acquired by a variety of institutional investors in the last quarter, including Deutsche Bank AG, AQR Capital Management LLC, Renaissance Technologies LLC, Schroder Investment Management Group, Marshall Wace LLP, BlackRock Inc., Canada Pension Plan Investment Board and NN Investment Partners Holdings N.V.. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert and Warren Russell Hawkins. View Insider Buying and Selling for ResMed. How do I buy shares of ResMed? Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ResMed's stock price today? One share of RMD stock can currently be purchased for approximately $112.90. How big of a company is ResMed? ResMed has a market capitalization of $15.67 billion and generates $2.34 billion in revenue each year. The medical equipment provider earns $315.58 million in net income (profit) each year or $3.53 on an earnings per share basis. ResMed employs 5,940 workers across the globe. What is ResMed's official website? The official website for ResMed is http://www.resmed.com. How can I contact ResMed? ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected] MarketBeat Community Rating for ResMed (NYSE RMD)Community Ranking: 1.7 out of 5 ()Outperform Votes: 260 (Vote Outperform)Underperform Votes: 527 (Vote Underperform)Total Votes: 787MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?